{"id":687556,"date":"2022-09-21T09:38:08","date_gmt":"2022-09-21T13:38:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/"},"modified":"2022-09-21T09:38:08","modified_gmt":"2022-09-21T13:38:08","slug":"effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/","title":{"rendered":"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference"},"content":{"rendered":"

\n– Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET –
\n<\/h2>\n
\n

SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1×1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference.<\/p>\n\n\n\n\n\n\n
Panel Topic:<\/td>\n\n
\n \u201cBuilding Combinations: What are the Novel Ideas?\u201d<\/em>
\n <\/strong>\n <\/td>\n<\/tr>\n
Date:<\/td>\nWednesday, September 28, 2022<\/td>\n<\/tr>\n
Time:<\/td>\n10:40 AM ET<\/td>\n<\/tr>\n
Panel Participant:<\/td>\nSteve Worland, Ph.D., President and Chief Executive Officer<\/td>\n<\/tr>\n
Conference Website<\/td>\n\n https:\/\/www.cantor.com\/cantor-oncology-hemonc-conference\/<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

\n About eFFECTOR Therapeutics<\/strong>\n <\/p>\n

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR\u2019s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR\u2019s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR\u2019s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR\u2019s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company\u2019s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n\n\n\n
\n Investors:<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Media:<\/strong>\n <\/td>\n<\/tr>\n
Christopher M. Calabrese
Managing Director
LifeSci Advisors
917-680-5608
ccalabrese@lifesciadvisors.com<\/p>\n<\/td>\n		Kevin Gardner
Managing Director
LifeSci Advisors
617-283-2856
kgardner@lifesciadvisors.com<\/td>\n		Heidi Chokeir, Ph.D.
Managing Director
Evoke Canale
619-203-5391
Heidi.chokeir@evokegroup.com<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET – SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1×1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference. Panel Topic: \u201cBuilding Combinations: What are the Novel Ideas?\u201d Date: Wednesday, September 28, 2022 Time: 10:40 AM ET Panel Participant: Steve Worland, Ph.D., President and Chief Executive Officer Conference Website https:\/\/www.cantor.com\/cantor-oncology-hemonc-conference\/ About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to … <\/p>\n

Continue reading “eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687556","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\neFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET – SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1×1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference. Panel Topic: \u201cBuilding Combinations: What are the Novel Ideas?\u201d Date: Wednesday, September 28, 2022 Time: 10:40 AM ET Panel Participant: Steve Worland, Ph.D., President and Chief Executive Officer Conference Website https:\/\/www.cantor.com\/cantor-oncology-hemonc-conference\/ About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to … Continue reading "eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T13:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference\",\"datePublished\":\"2022-09-21T13:38:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/\",\"name\":\"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=\",\"datePublished\":\"2022-09-21T13:38:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference - Market Newsdesk","og_description":"– Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET – SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1×1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference. Panel Topic: \u201cBuilding Combinations: What are the Novel Ideas?\u201d Date: Wednesday, September 28, 2022 Time: 10:40 AM ET Panel Participant: Steve Worland, Ph.D., President and Chief Executive Officer Conference Website https:\/\/www.cantor.com\/cantor-oncology-hemonc-conference\/ About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to … Continue reading \"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-21T13:38:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference","datePublished":"2022-09-21T13:38:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/"},"wordCount":401,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/","name":"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=","datePublished":"2022-09-21T13:38:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDQzNyM1MTYzNzQ1IzIwODI1MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687556"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687556\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}